K

Kingsway Clinical Research | Etobicoke, Canada

Research site

(Unclaimed)

Location

1243 Islington Avenue Suite 1000, Etobicoke, Ontario, Canada

Site insights

Top conditions

Top treatments

Rocatinlimab

Ruxolitinib

LY3009104

Baricitinib

CTP-543

Humira®

Camoteskimab

Abrocitinib

ABP 654

PF-04965842

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

4 of 21 total trials

A Study of Barzolvolimab in Patients With Prurigo Nodularis

The purpose of this study is to assess the efficacy and safety of barzolvolimab in adults with prurigo nodularis.

Active, not recruiting

Prurigo Nodularis

Other: Matching Placebo

Biological: barzolvolimab

A Study to Assess Long-term Safety, Tolerability, and Efficacy of Rocatinlimab in Adult and Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-ASCEND)

The primary objective of this study is to describe the long-term safety and tolerability of rocatinlimab in participants with moderate-to-severe AD.

Active, not recruiting

Atopic Dermatitis

Other: Placebo

Drug: Rocatinlimab

Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata

The overall objectives of the study are to evaluate long-term safety of CTP-543 and to assess long-term effects of CTP-543 on treating hair loss in a...

Active, not recruiting

Alopecia Areata

Drug: CTP-543

Study to Evaluate Efficacy and Safety of PF-04965842 With or Without Topical Medications in Subjects Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis (JADE EXTEND)

B7451015 is a Phase 3 study to evaluate Abrocitinib with or without Topical Medications in patients aged 12 years and older who have moderate to seve...

Active, not recruiting

Dermatitis, Atopic

Drug: Abrocitinib 200 mg

Drug: Abrocitinib 100 mg